Subsequent Events (Details Narrative) - USD ($) |
3 Months Ended | 9 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
Apr. 03, 2026 |
Mar. 31, 2026 |
Mar. 31, 2025 |
Dec. 31, 2026 |
May 12, 2026 |
May 08, 2026 |
Apr. 01, 2026 |
Dec. 31, 2025 |
|
| Subsequent Event [Line Items] | ||||||||
| Research and development expenses | $ 413,000 | $ 1,099,000 | ||||||
| Fair value of common stock | $ 35,000 | $ 26,000 | ||||||
| Subsequent Event [Member] | ||||||||
| Subsequent Event [Line Items] | ||||||||
| Number of convertible preferred shares converted | 400 | |||||||
| Number of shares issued for convertible preferred stock | 881,058 | |||||||
| Share Price | $ 1.00 | |||||||
| Subsequent Event [Member] | Amended Advisory Agreement [Member] | ||||||||
| Subsequent Event [Line Items] | ||||||||
| Equity method investment, ownership percentage | 5.00% | |||||||
| Subsequent Event [Member] | Clinical Trial Agreement [Member] | ||||||||
| Subsequent Event [Line Items] | ||||||||
| Reserach and development funding description | The Research Program is being conducted for clinical research use. The budget for the Study, including without limitations, funding and resources, provides for up to approximately $3.8 million over the course of three years borne by the Company. The University of Minnesota and the Company will each have the right to publish the Study results. The 2026 GTB-5550 Clinical Trial Agreement may be terminated by the Company or the University of Minnesota at any time upon thirty days’ written notice to the other party, by the University of Minnesota immediately for health, welfare and safety reasons, or by either party if the other party materially breaches the 2026 GTB-5550 Clinical Trial Agreement, provided that the breaching party fails to cure such breach within thirty days. | |||||||
| Research and development expenses | $ 3,800,000 | |||||||
| Subsequent Event [Member] | Amended Advisory Agreement [Member] | ||||||||
| Subsequent Event [Line Items] | ||||||||
| Number of shares issued for convertible preferred stock | 400,000 | |||||||
| Advisory fee | $ 150,000 | |||||||
| Fair value of common stock | $ 164,000 | |||||||